Further study on treatment of clotting and fibrinolytic system in ‘long COVID’ patients recommended
Lazy COVID-19 According to the researchers, symptoms in “long-lasting” may be caused by an overload of inflammatory cells “trapped” inside insoluble microscopic blood clots. Stellenbosch University in South Africa.
Professor Racia Pretorius, a member of the university’s Department of Physiological Sciences, made the discovery with his research team while studying microscopic clots in blood samples from individuals with “prolonged COVID”.
“We found high levels of various inflammatory molecules implicated in microscopic clots present in the blood of individuals with long-term COVID,” Pretorius said in a news release. “Some of the molecules trapped are clotting proteins such as fibrinogen, as well as alpha(2)-antiplasmin”.
Francis Collins, longtime head of the NIH, to resign
Fibrinogen is a protein involved in clot formation, while the molecule, alpha(2)-antiplasmin, inhibits the breakdown of blood clots, the authors explain in the release.
According to health experts, usually, the body is in between the process of blood clotting (thickening of blood to prevent blood loss after injury) and fibrinolysis (breaking down of fibrin in the blood to prevent blood clotting). Able to maintain balance.
However, when high levels of alpha(2)-antiplasmin are present in the blood of patients infected with COVID-19 and those dealing with “long COVID,” the body’s ability to break down clots is significantly hindered, the researchers found. Explained study.
The researchers also noted an important finding, that blood plasma samples collected from acute COVID-19 and “chronic COVID” patients continue to accumulate insoluble pellets at the bottom of the specimen tubes.
According to the study, the research team was the first to report finding these microscopic clots in blood samples from COVID patients, helping to resolve another intriguing component of the disease.
Of particular interest is the simultaneous presence of persistent heterogeneous microscopic clots and a pathological fibrinolytic system, the authors said in their report.
The research teams said these findings provide further evidence that COVID-19 and “long COVID” had significant cardiovascular and clotting pathologies. He recommended further research into treatment therapies to support the clotting and fibrinolytic system in patients with “prolonged COVID” symptoms.
Mount Sinai South Nassau Chief of Infectious Disease Dr. Aaron Glatt, spokesman for the Infectious Disease Society of America, was not involved in the study, but he told Granthshala News: “This is an interesting but very preliminary finding that should be investigated first. Any diagnostic action can be taken based on this data.”
The hospital epidemiologist said, “We currently do not have a complete understanding of ‘prolonged COVID’ by any means, but hopefully this will be another piece in the puzzle that allows us to better understand this important and common complication of COVID.” And will allow to treat- 19 diseases.”
The study was peer-reviewed and published in the journalCardiovascular Diabetologyin August 2021.